SLC5A2 and diabetes mellitus: In addition to glycemic control, SGLT2 inhibitors were found to confer renoprotective benefits in patients with type 2 DM, as documented in large clinical randomized trials (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus [EMPA-REG OUTCOME] and CANagliflozin cardioVascular Assessment Study [CANVAS]) [18,19].